STOCK DUELS
AstraZeneca vs GSK - Official head-to-head comparisons for widely followed pairs.
Official Stock Duel · AZN/GSKPublished
AstraZeneca vs GSK
Compares AstraZeneca and GSK across growth, profitability, cash generation, valuation and balance-sheet signals.
Left side
AZN.LSE
Right side
GSK.LSE
Comparison categories
6
Generated: Jul 17, 2026, 04:30 AM
Data as of: 2026-07-16
Stock Duels· 23 analyses
Official head-to-head comparisons for widely followed pairs.
Head-to-Head
AZN
AstraZeneca PLC
2VS4
metrics
GSK
GSK plc
9.93%
Sales Growth
3.97%
23.51%
Return on Equity (ROE)
36.42%
15.95%
Return on Invested Capital (ROIC)
20.8%
$8.8B
Free Cash Flow
$6.6B
25.6
Price to Earnings (P/E)
13.67
14.33
EV/EBITDA
8.24
Datafin’s View
Britain’s pharma giants: AstraZeneca’s oncology momentum against GSK’s vaccines-and-medicines balance.
Both draw from the same market; the difference is the quality of the pipeline and the pace of growth. AstraZeneca carries clearer oncology momentum and a richer late-stage pipeline, while GSK balances vaccines and medicines at a more cautious valuation — growth against steadiness.
This analysis is for informational purposes only and is not investment advice; it is a repeatable research starting point using the same rules.
Factor Profile
AZN.LSE and GSK.LSE are compared inside each metric family.
Results
Latest published or live-generated results from the official Datafin analysis.
| # | Stock | Winner | Sales Growth | Return on Equity(ROE) | Return on Invested Capital(ROIC) | Free Cash Flow | Price to Earnings(P/E) | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 🇸🇪 | AZN.ST AstraZeneca PLC | - | 9.93% | 23.51% | 15.95% | $8.8B | 25.6 | 14.33 |
| 2 | 🇬🇧 | GSK.LSE GSK plc | 3.97% | 36.42% | 20.8% | $6.6B | 13.67 | 8.24 |
1🇸🇪
AZN.ST
AstraZeneca PLC
- Sales Growth
- 9.93%
- Return on Equity(ROE)
- 23.51%
- Return on Invested Capital(ROIC)
- 15.95%
- Free Cash Flow
- $8.8B
- Price to Earnings(P/E)
- 25.6
- EV/EBITDA
- 14.33
2🇬🇧
GSK.LSE
GSK plc
- Sales Growth
- 3.97%
- Return on Equity(ROE)
- 36.42%
- Return on Invested Capital(ROIC)
- 20.8%
- Free Cash Flow
- $6.6B
- Price to Earnings(P/E)
- 13.67
- EV/EBITDA
- 8.24
Methodology
Revenue Growthhigher is better
ROEhigher is better
ROIChigher is better
Free Cash Flowhigher is better
P/Elower is better
EV/EBITDAlower is better
Last 5 Updates
Jul 17, 2026, 04:30 AM2 companies
Entered:AZN.ST
Exited:AZN.LSE
Jul 10, 2026, 04:59 AM2 companies
List unchanged (refreshed).
May 31, 2026, 08:32 AM2 companies
First run.